Sequence: GWTLNSAGYLLGKINLKALAALAKKILdRdRdRdRdRdRdRdRdR
| Experiment Id | EXP002389 |
|---|---|
| Paper | Transportan-derived cell-penetrating peptide delivers siRNA to inhibit replication of influenza viru |
| Peptide | T9(dR) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 80 nmol (per well, 6-well plate; complexed with 20 nmol siNP) |
| Rna Concentration | 20 nmol (per well, 6-well plate) |
| Mixing Ratio | 4:1 (T9(dR):siRNA molar) |
| Formulation Format | non-covalent peptide/siRNA nanoparticles (electrostatic complex) |
| Formulation Components | T9(dR) + siNP mixed in PBS; 5% (w/v) glucose in PBS used for IV injections |
| Size Nm | 350.00 |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | MDCK; A549 (antiviral assay). Uptake shown in 293T, A549, MDCK, RAW with Cy3-siGFP. |
| Animal Model | |
| Administration Route | cell culture transfection (non-covalent complex); PR8 infection MOI=0.01 at 6 h post-treatment |
| Output Type | virus titer reduction (plaque assay) after PR8 infection |
| Output Value | |
| Output Units | |
| Output Notes | T9(dR)+siNP reduced PR8 viral titers in MDCK and A549 vs controls; reported higher inhibition efficiency than TP-delivered siNP (Figure 5). |
| Toxicity Notes | MTT: cell viability not substantially affected at 10 µM; estimated LD50 ~85 µM in 293T; reported low cytotoxicity vs TP. |
| Curation Notes |